These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27063491)

  • 1. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Med Chem; 2016; 13(1):22-27. PubMed ID: 27449794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
    Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.
    Marasini N; Giddam AK; Khalil ZG; Hussein WM; Capon RJ; Batzloff MR; Good MF; Toth I; Skwarczynski M
    Nanomedicine (Lond); 2016 Dec; 11(24):3223-3235. PubMed ID: 27830630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus.
    Marasini N; Giddam AK; Ghaffar KA; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Nanomedicine (Lond); 2016 May; 11(10):1223-36. PubMed ID: 27077314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.
    Marasini N; Ghaffar KA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Curr Drug Deliv; 2017; 14(5):701-708. PubMed ID: 27440071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
    Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
    PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
    Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
    mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving forward: a mucosal vaccine against group A streptococcus.
    Georgousakis MM; McMillan DJ; Batzloff MR; Sriprakash KS
    Expert Rev Vaccines; 2009 Jun; 8(6):747-60. PubMed ID: 19485755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
    Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
    J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A
    Jin S; Zhang J; Nahar UJ; Huang W; Alharbi NA; Shalash AO; Koirala P; Yang J; Kiong JJE; Khalil ZG; Capon RJ; Stephenson RJ; Skwarczynski M; Toth I; Hussein WM
    ACS Infect Dis; 2023 Aug; 9(8):1570-1581. PubMed ID: 37489053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
    Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyethylenimine: An Intranasal Adjuvant for Liposomal Peptide-Based Subunit Vaccine against Group A
    Dai CC; Yang J; Hussein WM; Zhao L; Wang X; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
    ACS Infect Dis; 2020 Sep; 6(9):2502-2512. PubMed ID: 32786276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
    Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.
    Zaman M; Abdel-Aal AB; Fujita Y; Phillipps KS; Batzloff MR; Good MF; Toth I
    PLoS One; 2012; 7(1):e30146. PubMed ID: 22253911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
    Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
    Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
    Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
    J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.